FDG-PET/MRI同步成像在I型神经纤维瘤病中的应用
该研究纳入28例NF1患者,用同步FDG-PET/MRI评估83个周围神经肿瘤(75个良性PNF、8个MPNST)。MPNST的SUVmean及SUVmean-肝脏比值显著高于PNF,SUVmax≥2.78为鉴别界值;PNF生长率与SUVmean正相关,而ADC、强化和目标征在组间无差异。
要点
- 同步FDG-PET/MRI可同时获取PNF的形态学与代谢信息。
- MPNST的SUVmean和SUVmean-肝脏比值显著高于良性PNF。
- SUVmax≥2.78可作为鉴别良性PNF与MPNST的界值。
核心结论
- 同步FDG-PET/MRI是监测NF1患者PNF的综合影像手段,可关联病灶生长率与代谢活性并定义识别恶变的SUV阈值。
研究设计与样本
- 回顾性纳入2012年9月至2018年2月在本机构接受同步FDG-PET/MRI的NF1患者,检查指征为怀疑PNF恶变为MPNST。
- 每例患者最多选取6个周围神经病灶作为靶病灶,测量SUV和ADC,并视觉记录目标征和对比剂强化。
主要发现
- 28例NF1患者共83个周围神经肿瘤作为靶病灶,其中75个为良性PNF,8个为MPNST。
- MPNST的SUVmean为3.84±3.98,PNF为1.85±1.03,差异有统计学意义(P<.01)。
- MPNST的病灶SUVmean-肝脏SUVmean比值为3.20±2.70,PNF为1.23±0.61,差异有统计学意义(P<.01)。
- PNF生长率与SUVmean呈显著正相关(rs=.41;P=.003)。
- ADCmean在PNF(1.87±0.24×10-3 mm2/s)与MPNST(1.76±0.11×10-3 mm2/s)间无显著差异(P>.05),对比剂强化(P=.50)和目标征(P=.86)亦无差异。
关键数值与推荐
- 定义SUVmax≥2.78作为鉴别良性PNF与MPNST的显著界值。
临床怎么用
- 对NF1患者怀疑PNF恶变时,可采用同步FDG-PET/MRI同时评估形态与代谢。
- 可参考SUVmax≥2.78作为提示恶性转化的界值,并结合病灶生长率综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To demonstrate the clinical use of FDG-PET/MRI for monitoring enlargement and metabolism of plexiform neurofibromas (PNF) in patients with neurofibromatosis type 1 (NF1), in whom the development of a malignant peripheral nerve sheath tumor (MPNST) is often a life limiting event. METHODS: NF1 patients who underwent a simultaneous FDG-PET/MRI examination in our institution from September 2012 to February 2018 were included. Indication was suspicion of malignant transformation of a PNF to MPNST. A maximum of six peripheral nerve lesions per patient were defined as targets. Standardized uptake values (SUV) and apparent diffusion coefficients (ADC) were measured. The presence of target sign and contrast-medium enhancement was visually recorded. Growth rates were estimated comparing prior or follow-up examinations and correlated with FDG uptake and ADC values. The presence of CNS lesions in cerebral T2 weighted images was recorded. RESULTS: In 28 NF1 patients a total number of 83 peripheral nerve tumors, 75 benign PNFs and eight MPNSTs, were selected as target lesions. The SUVs of MPNSTs were significantly higher than the SUVs of PNF (3.84 ± 3.98 [SUVmean MPNSTs] vs. 1.85 ± 1.03 [SUVmean PNF], P < .01). Similarly, lesion SUVmean-to-liver SUVmean ratios significantly differed between MPNSTs and PNF (3.20 ± 2.70 [MPNSTs] vs. 1.23 ± 0.61 [PNF]; P < .01). For differentiation between still benign PNF and MPNSTs, we defined SUVmax ≥ 2.78 as a significant cut-off value. Growth rate of PNF correlated significantly positively with SUVmean (rs = .41; P = .003). MRI parameters like ADCmean (1.87 ± 0.24 × 10-3 mm2/s [PNF] vs. 1.76 ± 0.11 × 10-3 mm2/s [MPNSTs]; P > .05], contrast medium enhancement (P = .50) and target sign (P = .86) did not differ between groups. CONCLUSION: Simultaneous FDG-PET/MRI is a comprehensive imaging modality for monitoring PNF in NF1 patients. The combined acquisition of both morphologic information in MRI and metabolic information in PET enables the correlation of lesion growth rates with metabolic activity and to define SUV thresholds of significance to identify malignant transformation, which is of utmost clinical significance.
引用
- Reinert CP, Schuhmann MU, Bender B, et al. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2018. PMID: 30535768. doi:10.1007/s00259-018-4227-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。